<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568983</url>
  </required_header>
  <id_info>
    <org_study_id>Optijuice</org_study_id>
    <nct_id>NCT01568983</nct_id>
  </id_info>
  <brief_title>The Effects of Polyphenol-rich Berry Juice on Blood Pressure in Hypertensive Subjects</brief_title>
  <official_title>The Effects of Polyphenol-rich Berry Juice on Blood Pressure and Additional CVD Related Parameters in Pre-hypertensive Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fellesjuice AS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nofima Mat AS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oslo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of berry juices containing different
      levels of polyphenols on blood pressure and other cardiovascular risk factors.

      The study is a 12 week double blinded randomized controlled intervention trial. The subjects
      will be divided in three groups where one receives a placebo juice while the two other will
      consume 0.5 liter of juice containing different levels of polyphenols. Blood pressure will be
      monitored and blood samples will be taken.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic and diastolic blood pressure</measure>
    <time_frame>Screening, baseline, 6 and 12 weeks</time_frame>
    <description>Change in blood pressure from baseline to 6 weeks and 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet aggregation</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in platelet aggregation from intervention start till end analyzed by PFA100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular disease risk factors</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The effect of polyphenole-rich diet on cardiovascular disease risk factors in blood samples will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diabetes related parameters in blood and urine</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The effect of different doses and types of polyphenoles on diabetes related biomarkers in blood and urine will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood cell expression of stress-response and CVD related genes</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Effect of polyphenole-rich diet on blood cell expression of stress-response and cardiovascular disease related genes by low density array and/or whole genome expression (microarray).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Polymorphisms in cardiovascular disease related genes</measure>
    <time_frame>Baseline</time_frame>
    <description>Single nucleotide polymorphisms will be analyzed and eventually grouped and compared with the mentioned outcome measures to reveal individual mechanisms of the hypothetized effects of the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole genome transcription profiles and methylation patterns</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Effects of polyphenoles on transcription profiles and methylation pattern will be analyzed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Pre-hypertension</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>12 weeks intake of 0.5 liter/day placebo juice containing sugar, aromas and salt corresponding to the berry juices in the other groups.
Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mana-juice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 weeks intake of 0.5 liter/day of a commercially available berry juice (Mana blue) rich in polyphenols (grape, cherries, bilberries and aronia).
Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optijuice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 weeks intake of 0.5 liter/day of berry juice rich in polyphenols (grape, cherries, blueberry and aronia) and added extract from press cake of black currant.
Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>500 ml/day Per 100g 6.25 g sucrose 6.25 g maltodextrin 1.3 g citric acid E330 (pH 3.0) 2.5 g Carmine solution E120 (4% carmine colouring agent) 0.025 g blueberry aroma Potassium sorbate E202 water</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mana-juice</intervention_name>
    <description>500 ml/day of a grape,cherry, bilberry,aronia juice 13g carbohydrates/100g 150mg K/100g</description>
    <arm_group_label>Mana-juice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Optijuice</intervention_name>
    <description>500 ml/day of a Grape,cherry, bilberry,aronia, black current juice 13g carbohydrates/100g 150mg K/100g</description>
    <arm_group_label>Optijuice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-hypertension or hypertension systolic blood pressure in the 130-179 mmHg range
             and/or diastolic blood pressure in the 85-109 mmHg range)

          -  BMI 20-35 kg/m2

          -  Stable weight (change &lt;4 kg previous 12 weeks)

        Exclusion Criteria:

          -  Regular use of blood pressure lowering agens

          -  Diabetes type I or II

          -  Smokers

          -  Allergy to grape, cherries, blueberries/bilberries, black currant, aronia

          -  Supplements for weight loss

          -  Changes in pharmacological treatment of hyperlipidemia or hyperglycemia (initiation,
             termination or changes in dosage) last 30 days prior to inclusion or during the study
             period (run-in and intervention)

          -  Participation in a drug trial during the previous 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rune Blomhoff, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oslo</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>June 29, 2012</last_update_submitted>
  <last_update_submitted_qc>June 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oslo</investigator_affiliation>
    <investigator_full_name>Rune Blomhoff</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

